TO WHOM IT MAY CONCERN

The Conjoint Health Research Ethics Board (CHREB) of the University of Calgary reviews biomedical and health research protocols involving human subjects submitted by investigators from the University of Calgary Cumming School of Medicine, Faculty of Nursing and Faculty of Kinesiology, and protocols from Mount Royal University seeking health information access. The CHREB’s jurisdiction extends to research conducted under the auspices of the University of Calgary Cumming School of Medicine, Faculty of Nursing and Faculty of Kinesiology.

For privacy reasons, the CHREB does not release the names of its members.

The designations of the members of the CHREB are as follows:

• Chair
• Member(s) from the community who is unaffiliated with the Institution;
• Member(s) of the Cumming School of Medicine, Faculty of Nursing and Faculty of Kinesiology with knowledge in relevant scientific disciplines, clinical/therapeutic fields or research methods covered by the CHREB;
• Member(s) whose primary interests and background is non-scientific;
• Member(s) with expertise in complementary and alternative medicines (CAMs);
• Member(s) knowledgeable in the relevant laws; and
• Member(s) knowledgeable in ethics.

There is equitable gender representation on the Board.

Board members recuse themselves from the consideration of studies (including discussion and voting) on which they are investigators.

Quorum is ensured at the start of each meeting, and is set as at least 50% plus one.

The Board has current accreditation with US Federalwide Assurance (FWA) for protection of human subjects and is a registered IRB. The Board functions in compliance with national and local regulations. In particular the Board complies with the requirements and policies of the Tri-Council Policy Statement: Ethical Conduct for Research Involving Humans (current version); the International Conference on Harmonization – Good Clinical Practice Guideline (current version); the Health Information Act, R.S.A., 2000 c. H-5; and the Food and Drugs Act, R.S.C., 1985, c. F-27.

Sincerely,

Stacey A. Page, PhD
Chair, Conjoint Health Research Ethics Board
Associate Professor
Department of Community Health Science
Federalwide Assurance (FWA)#: 00000810
Institutional Review Board (IRB)#: 00001300

TO WHOM IT MAY CONCERN

The purpose of this letter is to confirm that the Conjoint Health Research Ethics Board (CHREB) complies with the membership requirements and operates in compliance with:

- The Tri-Council Policy Statement - Ethical Conduct for Research Involving Humans (current version)
- The International Conference on Harmonization – Good Clinical Practice Guideline (current version)
- The Health Information Act, R.S.A., 2000 c. H-5
- The Food and Drugs Act, R.S.C., 1985, c. F-27
- The Food and Drugs Act, R.S.C., 1985, c. F-27, subsection 30.1 (1) annex: Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19

The CHREB has reviewed and approved the clinical trial protocol and informed consent form for the trial which is to be conducted by the qualified investigator named on the application at the specified clinical trial site. This approval and the views of this Research Ethics Board have been documented in writing.

Sincerely,

Stacey A. Page, PhD
Chair, Conjoint Health Research Ethics Board
Associate Professor
Department of Community Health Science